Drug discovery is inherently a multicriteria optimization problem.
Mathematical Models of Ocular Drug Delivery
Drug delivery is an important factor for the success of ocular drug treatment.
The Application of Artificial Intelligence/Machine Learning in Drug Development and Regulation
Artificial intelligence/machine learning (AI/ML) are increasingly being utilized in drug development.
Optimization of wet granulation process for manufacturing Rivaroxban generic immediate-release tablets using PBPK modeling and simulations
Granulation is the critical process for the pharmaceutical development of poorly water-soluble drug products.
Women in Science: Evelyn Haupt
In the biopharma industry, we often focus on scientific research and research methodologies. However, software design and usability is also vital in translating complex data and technologies into accessible and user-friendly solutions.
A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation
Physiologically based pharmacokinetic (PBPK) or physiologically based biopharmaceutics models (PBBM) demonstrated plethora of applications in both new drugs and generic product development.
Novel omeprazole delayed release orally disintegrating tablets for enhanced patient compliance: a case of model informed formulation development
The advanced in silico simulation tools, such as physiologically based biopharmaceutics models (PBBM) or physiologically based pharmacokinetic models (PBPK), play critical role in model informed formulation development.
Predicting dose-dependent fraction absorbed via a mechanistic absorption model and machine learning
Drug dissolution and absorption are crucial in oral drug delivery.
A Physiologically Based Pharmacokinetic Model of Voriconazole in Human CNS —— Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Possible Transporter Mechanisms
Voriconazole is a classical antifungal drug that is often used to treat CNS fungal infections due to its permeability through the BBB.
EvolvePK+ Comparison Flyer
Only one platform can integrate GastroPlus PBPK outcomes during early design and lead optimization.
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
Various small molecule GLP1R agonists have been developed and tested for treating type 2 diabetes (T2DM) and obesity.
3 Clinical Quality Problems That Simulation Training Solves
Want to see fewer protocol deviations and agile change management in your clinical trials while also reducing burdens on research site staff?
Targeting Complement to Reduce Disease Activity: Challenges and Opportunities in the Publicly Available Data (Part Two)
In part one of this complement blog series, the complement cascade and its role in various diseases was introduced, as well as the potential for mechanistic modeling to support development of complement‑targeted therapeutics. COMPLEMENTsym, a quantitative systems pharmacology (QSP) model of complement focused on the alternative and terminal pathways (AP, TP, respectively) was introduced.
Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach
Propylthiouracil (PTU) and methimazole (MMI), two classical antithyroid agents possess risk of drug-induced liver injury (DILI) with unknown mechanism of action.
Redefining Statin Dosage Post-Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach
Roux-en-Y gastric bypass (RYGB) involves creating a small stomach pouch, bypassing part of the small intestine, and rerouting the digestive tract.
Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation
LNA-i-miR-221 is a novel microRNA(miRNA)-221 inhibitor designed for the treatment of human malignancies.
Simulations Plus Releases DILIsym® X
Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI)
Don’t Wait Until Phase III: Why Early DILI Prediction is Key to Drug Development Success
As anyone who has worked in the pharmaceutical industry for awhile can tell you, there are many challenges, but one in particular keeps many of us up at night – the specter of drug-induced liver injury (DILI) lurking later in the drug development process.
Simulations Plus Releases ADMET Predictor® Version 12
Enhancements in key models power HT-PBPK simulations and AI-driven drug design with unprecedented performance and accuracy.
ADMET Predictor®12: Predict with Confidence
Stay ahead of the competition with ADMET Predictor® 12!